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ABSTRACT Small intestine luminal nutrient sensing
may be crucial for modulating physiological functions.
However, its mechanism of action is incompletely un-
derstood. We used a model of enteral nutrient depri-
vation, or total parenteral nutrition (TPN), resulting in
intestinal mucosal atrophy and decreased epithelial
barrier function (EBF). We examined how a single
amino acid, glutamate (GLM),modulates intestinal epithelial
cell (IEC) growth and EBF. Controls were chow-fed
mice, T1 receptor-3 (T1R3)-knockout (KO) mice, and
treatment with the metabotropic glutamate receptor
(mGluR)-5 antagonistMTEP. TPN significantly changed the
amount of T1Rs, GLM receptors, and transporters, and
GLM prevented these changes. GLM significantly pre-
vented TPN-associated intestinal atrophy (2.5-fold in-
crease in IEC proliferation) and was dependent on
up-regulation of the protein kinase pAkt, but indepen-
dent of T1R3 and mGluR5 signaling. GLM led to a loss
of EBF with TPN (60% increase in FITC-dextran per-
meability, 40% decline in transepithelial resistance); via
T1R3, it protected EBF, whereas mGluR5 was associ-
ated with EBF loss. GLM led to a decline in circulating
glucagon-like peptide 2 (GLP-2) during TPN. The
decline was regulated by T1R3 and mGluR5, suggesting
a novel negative regulator pathway for IEC prolifera-
tion not previously described. Loss of luminal nutrients
with TPN administration may widely affect intestinal
taste sensing. GLM has previously unrecognized actions
on IEC growth and EBF. Restoring luminal sensing via
GLM could be a strategy for patients on TPN.—Xiao,
W., Feng, Y., Holst, J. J., Hartmann, B., Yang, H.,
Teitelbaum, D. H. Glutamate prevents intestinal atrophy via
luminal nutrient sensing in a mouse model of total paren-
teral nutrition. FASEB J. 28, 2073–2087 (2014).
www.fasebj.org
Key Words: proliferation  epithelial barrier function  taste
receptor  metabotropic glutamate receptor
The gastrointestinal (GI) mucosa responds to a vast
array of signals originating in the lumen, including
nutrient and nonnutrient stimuli. Subsequently, these
signals modulate physiological functions, including di-
gestion, absorption, secretion, and protection from
hazardous intraluminal contents (1). In recent years,
there has been growing interest in luminal signaling
pathways in the GI tract and in elucidating the possible
roles and the underlying mechanisms of gut luminal
sensing in various physiological and pathologic condi-
tions. Recent studies have demonstrated that G-protein-
coupled receptors (GPCRs), typically taste receptors
(TRs) via G-protein subunits, play a key role in luminal
molecule recognition and initiate luminal signaling
pathways by activation of enteroendocrine cells and
nerve fibers (2, 3). This signaling has been shown to
integrate luminal sensing processes at different levels
and thereby to modulate physiological responses in the
GI tract, as well as to activate mucosal defense mecha-
nisms (4). Moreover, evidence is accumulating that
altering the content of the GI lumen may lead to
disease states ranging from feeding disorders to inflam-
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mation (5). However, despite the clinical importance,
effective strategies for preventing inappropriate lumi-
nal sensing responses from various pathologic stimuli
are still needed. Total parenteral nutrition (TPN), or
the intravenous feeding of patients, is used in clinical
patient care almost 400,000/yr in the United States
(6). However, there is a substantial body of evidence
that TPN can lead to complications, including the
development of mucosal atrophy and loss of intestinal
epithelial barrier function (EBF), both of which may
contribute to an associated increase in clinical infec-
tions and loss of immune reactivity (7). However, the
underlying mechanisms contributing to TPN-associated
intestinal atrophy and EBF dysfunction are not fully
understood. Because TPN is accompanied with a loss of
nutrients within the GI lumen, it presents as a very
powerful tool for understanding the mechanisms that
guide luminal sensing of a single nutrient. By this
method, a single nutrient can be examined in isolation
without the interference of nutrients that would con-
found the results. In addition, the influence that this
single nutrient may have on the TPN-induced intestinal
mucosal atrophy and EBF dysfunction allows for a very
precise way to track such physiological changes. In this
study, we tested whether it is possible to prevent devel-
opment of this TPN-associated GI physiological pheno-
type through restoring luminal sensing signaling with a
specific tastant.
Glutamate (GLM) is a basic taste stimulant that
mediates the umami taste (8). It has been shown to be
closely involved in luminal chemosensing in duodenal
mucosa, via multiple GPCRs, including the T1 receptor
(T1R) TR family, namely, the T1R1/T1R3 heterodimer,
and the metabotropic GLM receptors (mGluRs) (9–
11). Luminal GLM perfusion significantly enhances
duodenal mucosal defense mechanisms against injury
due to acid exposure (11). GLM also has the capability
of stimulating the proliferation of several kinds of cells
outside the GI tract (12). Thus, we hypothesized that
GLM would drive intestinal epithelial cell (IEC) prolif-
eration and prevent TPN-associated mucosal atrophy
through modulating luminal sensing signaling in the
GI mucosa.
This study was conducted to assess the possible
alteration of luminal sensing signaling in the small
intestine during TPN administration, with or without
oral GLM supplementation. The present results dem-
onstrate the novel finding that GLM can drive IEC
proliferation and prevent TPN-associated atrophy. In-
terestingly, our study also demonstrated a dose-depen-
dent modulation of EBF action and identified unique
signaling pathways, by which GLM can influence EBF in
TPN-fed mice (hereafter referred to as TPN mice).
Therefore, modulation of luminal sensing via GLM
signaling affects not only IEC proliferation, but also
EBF in TPN mice. In the present work, we identified a
differential action of GLM via T1R3 that promoted
EBF, whereas mGluR5 signaling led to EBF loss. The
study also showed that GLM’s promotion of IEC prolif-
eration was associated with a decline in circulating
glucagon-like peptide 2 (GLP-2), suggesting a novel
negative regulator mechanism of IEC proliferation.
Although an optimal dose remains to be determined,
the current work suggests a potentially important role
for GLM in protecting patients receiving TPN against
the associated intestinal atrophy and in minimizing
TPN=s negative effects on EBF.
MATERIALS AND METHODS
Animals
C57BL/6 male, specific pathogen-free 10- to 11-wk-old mice
(Jackson Laboratory, Bar Harbor, ME, USA) were maintained
under temperature-, humidity-, and light-controlled condi-
tions. Body weight- and age-matched adult male T1R3-knock-
out (T1R3KO; B6;129-Tas1r3tm1Csz/J) mice with a C57BL/6
background (Jackson Laboratory) were also studied. The
mice were initially fed standard mouse chow and water ad
libitum and allowed to acclimate for 1 wk before surgery.
During the administration of intravenous solutions, the mice
were housed in metabolic cages to prevent coprophagia. The
study protocol was approved by the University of Michigan
Committee on the Use and Care of Animals (approval 7703).
Operative procedures and TPN delivery
Cannulation and administration of TPN was identical with
that previously described (13, 14). TPN mice received intra-
venous TPN at 4.8 ml/d. Nitrogen and energy delivery was
matched between groups (isonitrogenous/isocaloric). This
TPN solution, and the administration rate, allows for ade-
quate caloric delivery, matching the amount that the enterally
fed mice received (14, 15). The TPN  GLM group received
monosodium glutamate (MSG; Ajinomoto Co. Inc., Tokyo,
Japan) at 75 mM diluted in drinking water (5 ml/d), starting
the day of cannulation. The TPN group that was not given
GLM received a reduction in the crystalline amino acids to
match the nitrogen delivery in the TPN  GLM (75 mM)
group. The sham-treatment group consisted of enterally fed
mice given intravenous saline at the same rate as the infusions
in the TPN group (5 ml water/d).
3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP; R&D Sys-
tems, Minneapolis, MN, USA) was used to block mGluR5’s
activity and was diluted with saline and administered intra-
peritoneally via the indwelling catheter at 30 mg/kg daily,
beginning on the day of cannulation. In the respective
control group, MTEP was replaced with saline.
Mice were killed with CO2 7 d after cannulation. Body
weight was recorded on the day of cannulation and the 7th
day after cannulation. The amount of water taken by the mice
was measured daily to ensure that the mice took the appro-
priate amount of GLM-treated water. Mice were euthanized
before the end of the 7 d period if their health deteriorated
to a level found to be unacceptable for their well-being and
were not included in the final data analysis. All experiments
were performed with 6 mice/group.
RNA isolation and quantitative RT-PCR
RNA extraction from mucosal scrapings was performed ac-
cording to published procedures (16, 17). Quantitative PCR
was measured with a Rotor-Gene 6000 (Corbett Life Science,
Sydney, NSW, Australia), and -actin was used as the internal
control for normalization. For the initial screening of candi-
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date TRs, GLM receptors, and transporters, a customized RT2
Profiler PCR Array was used (SABioscience; Qiagen, Freder-
ick, MD, USA).
Western immunoblot analysis
The isolation of IECs and Western blot analysis were per-
formed (18) with antibodies (Abs) including rabbit anti-T1R3
(1:200; ab-74732; Abcam, Cambridge, UK), rabbit-anti--gust-
ducin (G; 1:400; sc-395; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), rabbit anti-mGluR2/3 (1:250; ab-6438; Ab-
cam), rabbit anti-mGluR4 (1:400; ab-6438; Abcam), rabbit
anti-mGluR5 (1:300; ab-53090; Abcam), rabbit anti-EAAT2
(1:400; SC-15317; Santa Cruz Biotechnology), rabbit anti-
EAAT3 (1:400; SC-25658; Santa Cruz Biotechnology), rabbit
anti-zona occludens 1 (ZO-1; 1:250; 617300; Life Technolo-
gies, Grand Island, NY, USA), mouse anti-occludin (1:200;
331500; Life Technologies), rabbit anti-phospho-Akt (pAkt)-
1/2/3 (Ser473 and Thr308; 1:200; sc-25658; Santa Cruz
Biotechnology), rabbit anti-Akt (pan; C67E7; 1:400; 4691;
Cell Signaling Technology, Beverly, MA, USA), mouse anti-
proliferating cell nuclear antigen (PCNA; 1:3000; 2586, Cell
Signaling Technology), and mouse anti--actin (1:1000; sc-
130300; Santa Cruz Biotechnology). The secondary Ab was
the horseradish peroxidase conjugate of either goat anti-
mouse or goat anti-rabbit IgG (1:2000; Santa Cruz Biotech-
nology).
Immunofluorescence (IF) microscopy
Sections (10 m) of jejunum were embedded and frozen in
optimal cutting temperature (OCT) compound (Tissue-Tek;
Sakura Finetek, Tokyo, Japan). IF staining was performed
(16) with concentrations of the primary Abs as follows: 1:3000
PCNA, 1:50 5-bromo-2-deoxy uridine (BrdU), 1:250 ZO-1,
and 1:150 occludin.
IEC proliferation assessment
IEC proliferation was assessed by IF staining of the markers
PCNA and BrdU. For BrdU detection, all mice received BrdU
(000103; BrdU labeling reagent; Life Technologies) at 50
mg/kg via i.p. injection 2 h before death (19). An index of
the crypt cell proliferation rate was expressed as the ratio of
the number of PCNA- or BrdU-positive cells per crypt to the
total number of crypt cells. The total number of proliferating
cells per crypt was defined as the mean of proliferating cells
in 10 crypts for each mouse. Immunoblot density of PCNA
was also used as a measure of the IEC proliferation rate.
Intestinal morphology assessment
Villus height and crypt depth were measured in 10 well-
oriented, full-length crypt-villus units per specimen and aver-
aged. Data were analyzed with commercially available digital
image analysis software (NIS-Elements, AR 3.0; Nikon, Mel-
ville, NY, USA).
Ussing chamber and permeability studies
Experiments were performed in modified Ussing chambers
(Physiological Instruments, San Diego, CA, USA) on jejunal
segments (20). The transmembrane resistance (TER) was
determined according to Ohm’s law. The permeability of the
jejunum was also assessed by measuring the mucosal-to-
serosal permeation of FITC-dextran (FD4; average molecular
weight, 3000–5000; Sigma-Aldrich, St. Louis, MO, USA; ref.
21). Briefly, 150 l FITC-dextran (50 mg/ml, diluted with
fresh Krebs buffer) was added to the mucosal compartment
after a 30 min equilibration period. Then, a 1 ml sample was
removed from the serosal compartment after 60 min, kept in
80°C for subsequent fluorescence quantitative analysis, and
replaced by the same volume of fresh Krebs buffer. Fluores-
cence was measured with a Synergy 2 multimode microplate
reader (BioTek Instruments, Winooski, VT, USA) at an
excitation wavelength of 492 nm and an emission wavelength
of 515 nm. Permeability was expressed as the percentage of
mucosal-to-serosal clearance of FITC-dextran.
Plasma GLP-2 measurements
Plasma GLP-2 was measured by radioimmunoassay with an
N-terminal specific antiserum that measures only GLP-2 with
an intact N terminus (22). DPP4 inhibitor (2 l; EMD
Millipore, Billerica, MA, USA) was added in the collected
blood samples to avoid GLP-2 degradation.
Statistical analysis
Data are expressed as means  sd. A preliminary power
analysis determined that a minimum of 6 subjects/study
group would be needed on the basis of previous variance data
from proliferation assays, our primary outcome measure.
Paired t tests were used for comparing 2 groups. Significance
was defined as P  0.05.
RESULTS
TPN induces altered mRNA expression of T1Rs,
GLM receptors, and transporters in the jejunum, and
oral GLM supplementation prevents these
TPN-associated changes
It is presently unknown how luminal sensing molecules
are affected by enteral nutrient deprivation (i.e., TPN).
Therefore, a specially designed mRNA array was cre-
ated to study the gene expression profile, including
TRs, GI receptors [GLM receptors (GLMRs)], and
transporters involved in gut luminal sensing signaling
in TPN mice. From this screening, 13 genes were found
to be significantly altered by TPN. As shown in Table 1,
compared with levels in the sham-treatment (enterally
fed) group, TPN led to significant changes in the level
of several T1Rs, GLMRs, and selected nutrient trans-
porters. Surprisingly, of the 3 T1Rs, T1R1 and T1R3,
which form a heterodimeric complex for effective
umami taste sensing, both showed an upregulation of
mRNA expression to various degrees during TPN ad-
ministration. In contrast, T1R2 expression, which me-
diates sweet taste sensing, displayed a significant de-
crease. TPN also induced a significant decline in the
mRNA expression of mGluR5 and a significant upregu-
lation of mGluR7; glutamate receptor, ionotropic, kai-
nate 5 (GRIK5); and GluR1. In addition, several trans-
porters, including excitatory amino acid transporter 2
and 3 (EAAT2 and EAAT3) and sodium glucose
cotransporter 1 (SGLT-1), displayed a significant down-
regulation during TPN treatment (Table 1). However,
supplementation with oral GLM induced an upregula-
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tion of mRNA level in most T1Rs, GLMRs, and trans-
porters to various degrees, suggesting that GLM signif-
icantly stimulates luminal sensing signaling in the small
intestine of TPN mice.
Next, IF staining of 3 T1Rs in the present study was
identified in the cytoplasm of endocrine-like solitary
cells dispersed throughout the villus epithelium, with
rare cells identified in the jejunal glands having the
configuration of enteroendocrine cells (Fig. 1A). This
observation suggests that enteroendocrine cells play an
important role in the intestinal TR signaling pathway,
and the distribution of these T1Rs was similar to that
previously reported (23). The localization of each of
the T1Rs was similar between the sham-treatment, TPN,
and TPN  GLM groups. No differences were noted in
staining intensity or number of T1R cells; however,
TABLE 1. mRNA alteration of luminal sensing molecules, including T1Rs, GLM receptors, and
transporters in the jejunal mucosa of TPN mice, with or without GLM supplementation (75 mM)
Molecule Sham TPN TPN  GLM
T1R1 0.76  0.34 2.37  0.53* 2.89  0.81*
T1R2 3.72  1.09 1.34  0.14* 5.21  2.52#
T1R3 4.20  1.48 6.49  2.37 14.78  1.50*,#
mGluR3 1.25  0.70 1.16  0.40 5.56  1.51*,#
mGluR4 2.74  0.87 2.97  1.15 5.66  0.64*,#
mGluR5 3.30  1.02 1.29  0.75* 4.48  1.07*,#
mGluR7 0.98  0.18 2.56  0.84* 4.65  1.67*,#
GluR1 1.98  1.55 3.93  1.99* 7.29  1.99*,#
GRIK5 0.73  1.99 1.99  0.79* 1.38  0.28*
EAAT2 1.47  0.40 0.20  0.04* 0.61  0.16*,#
EAAT3 3.54  1.30 1.61  0.55* 4.39  1.74#
VGLUT3 2.14  0.56 5.02  2.21* 11.25  1.62*,#
SGLT1 1.09  0.35 0.66  0.24* 1.45  0.72#
Values are means  sd. *P  0.05 vs. sham-treatment group; #P  0.05 vs. TPN group.
Figure 1. Influence of TPN administration and GLM supplementation on the amount of luminal sensing molecules of isolated
IECs at the protein level. A) IF staining was performed on jejunal mucosa from TPN mice with anti-T1Rs and anti-G Abs and
counterstained with DAPI nuclear stain. Note the similar localization of 3 T1Rs and G proteins in the cytoplasm of the
endocrine-like solitary cells of the jejunal villi. B, C) Protein expression of T1R3, mGluRs, transporters, and G in
sham-treatment mice compared with TPN and TPN  GLM (75 mM) mice. B) Representative immunoblots of isolated
small-bowel IECs from each group. C) Mean protein level for each group. For representative images and immunoblots, a
minimum of 3 experiments and images were used for each selection. Scale bars 	 50 m. Values are means  sd (error bars).
ns, not significantly different. *P  0.05.
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the fluorescence intensity of these cells and the overall
number were quite low, making quantitative differenti-
ation difficult. Consistent with the result of PCR analy-
ses, T1R3 protein expression analysis showed a 1.6-fold
increase in the TPN group and a 2.4-fold rise in the
TPNGLM mice, compared with expression in the
sham group. Unfortunately, we were unable to obtain
ideal immunoblot results of T1R1 and T1R2 because of
the presence of a very high background and relatively
weak signal of the target blots. A similar problem has
been identified by several other groups; these research-
ers found that the poor quality of the currently avail-
able antibodies and the low level of TRs contribute to
the difficulty of quantitative analysis of T1R expression
(24–26).
Of note, immunoblot results for mGluRs varied
compared with mRNA expression. As shown in Fig. 1B,
the expression of mGluR2/3, mGluR4, and mGluR5
was down-regulated during TPN administration. As
well, the expression level of mGluR2/3 and mGluR4
proteins declined even further with GLM supplemen-
tation, whereas mGluR5 showed a significant up-regu-
lation. This result suggests that different mGluRs play
distinct roles in GLM-mediated actions in modulating
luminal sensing. In addition, the expression of the
GLM transporters EAAT2 and EAAT3 showed a signif-
icant decrease in the TPN mice and an increase in the
TPN  GLM group at the protein level, similar to the
mRNA results.
It is well recognized that all T1Rs and mGluRs belong
to GPCRs, with transmembrane domains to facilitate
taste sensing (8, 27). These GPCRs activate G proteins,
most notably -gustducin (G), to transduce taste
signaling to downstream signaling molecules (3). In the
current study, IF staining results demonstrated a similar
localization of G protein in the IECs, as seen with T1R
staining (Fig. 1A), suggesting a possible colocalization
with T1Rs in enteroendocrine cells, as described in a
previous study (24). However, we failed to obtain ideal
colocalization images of G with T1Rs. Immunoblot
analysis showed that G protein expression in the TPN
group significantly dropped (to 
30% of that in sham-
treated mice), whereas GLM supplementation com-
pletely prevented this reduction (Fig. 1B, C). This result
suggests that TPN simultaneously influences the ex-
pression of GPCRs and the G protein G and affects the
downstream taste signaling cascades, whereas GLM
prevents the loss of intestinal luminal sensing via
stimulation of umami TRs and reactivation of G
transduction.
GLM stimulated IEC proliferation in TPN mice and
prevented TPN-induced intestinal atrophy
As shown in Fig. 2A, after TPN administration, both
jejunal villus length and crypt depth decreased to 
40
and 
70% of those in the sham-treatment group,
respectively, whereas GLM supplementation signifi-
cantly increased villus height to 62% of the sham-
treatment group, suggesting that oral GLM supplemen-
tation results in significant prevention of the intestinal
atrophy associated with TPN administration.
To determine the mechanisms that led to GLM’s
preventing TPN-associated atrophy, we next examined
IEC proliferation rates. IF staining demonstrated that
the PCNA-positive rate in intestinal mucosal crypts of
the TPN mice dropped to 
37% of that in the sham-
treatment group; however, proliferation rates rose to
89% of sham-treated controls when supplemented with
GLM (Fig. 2B). This result was confirmed with BrdU
staining, with similar changes in IEC proliferation rates
between these methods of measurement. To further
confirm these changes in proliferation, we performed
both PCR and immunoblot analysis of PCNA expres-
sion, and the results were similar to those seen with IF
staining (Fig. 2C). Thus, GLM supplementation led to a
significant prevention of TPN-associated loss of IEC
proliferation. It should be noted that there was no
significant change in body weight throughout the TPN
period between the TPN and TPN  GLM groups (data
not shown). In addition, the water intake of the TPN
mice supplemented with GLM did not obviously differ
from that of the nonsupplemented TPN mice (data not
shown).
It is known that TPN-induced intestinal mucosal
atrophy is also due to an increase in epithelial cell (EC)
apoptosis (17). Therefore, an assessment of the effect
that GLM might have on IEC apoptosis rates was
performed with active caspase-3 staining. However,
GLM showed no obvious effect on apoptosis, and there
was no significant difference in apoptosis IEC-positive
rates between the TPN and TPN  GLM groups
(Supplemental Fig. S1). This result was further con-
firmed by immunoblot analysis of apoptosis-associated
protein Bcl-2 and Bax. As well, the mRNA levels of
caspase-3 were not significantly different between the
TPN and TPN  GLM groups (0.0300.001 vs. 0.04
0.002, respectively).
GLM restored pAkt expression, which was
down-regulated during TPN
Our laboratory has recently reported a significant loss
of pAkt signaling with TPN administration and the key
role of pAkt signaling in modulating EC proliferation
in the TPN mice (19). Consistent with this, the present
work showed a significant decrease in jejunal pAkt
expression in the TPN mice compared with that in the
sham-treatment group (Fig. 3). Interestingly, GLM
supplementation fully prevented the decline in pAkt
expression, with amounts returning to sham-treatment
levels. This result suggests that pAkt signaling plays an
important role in the proproliferation mechanism of
GLM on IECs in this TPN model.
GLM supplementation influenced EBF dysfunction
induced by TPN administration
Besides intestinal mucosal atrophy, EBF dysfunction is
another important physiological manifestation associ-
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ated with TPN administration and may contribute to
the increasing rates of systemic infections and septice-
mia (28). Interestingly, GLM supplementation at 75
mM in the TPN mice led to a significant (1.6-fold)
increase in FITC-dextran permeability and a 0.6-fold
decrease in TER value in jejunal mucosa, when com-
pared the same measures in the nonsupplemented
TPN group (Fig. 4A, B). Of note, this change in TER
and FITC-dextran permeability was highly dose depen-
dent, with the higher concentration (75 mM) of GLM
resulting in a loss of EBF, whereas 25 mM had no
obvious effect on EBF (Supplemental Fig. S2). In
addition, administering GLM to the enterally fed mice
(sham-treatment group) had no effect on either TER
or dextran permeability. It should be noted that there
was no obvious difference in survival between the GLM
and non-GLM TPN groups (survival in both was 
75%;
data not shown), suggesting that GLM supplementa-
Figure 2. GLM supplementation prevents the intestinal
atrophy induced by TPN. A) Hematoxylin and eosin
staining was performed on jejunum from sham-treat-
ment, TPN, and TPN  GLM mice (100). Villi length
and crypt depth of the jejunal mucosa in the TPN mice
were significantly shortened, compared with the sham-
treatment group, whereas GLM supplementation (75
mM) markedly increased jejunal villi length in the TPN
mice. Left panels: representative images of 3 groups.
Right panels: changes in the jejunal villi and crypts of
each study group. B) IF staining was performed on
jejunal mucosa from the sham-treatment, TPN, and TPN
GLM groups with anti-PCNA and anti-BrdU Abs and
counterstained with DAPI. Left panels: representative
images of 3 groups. Right panels: PCNA- or BrdU-
positive rate in the intestinal mucosal crypt of each group. Note the significant decrease in PCNA- and BrdU-positive rates
in the TPN group compared with that in the sham-treatment group, whereas GLM supplementation (75 mM) significantly
increased the PCNA- and BrdU-positive rates in the TPN mice. C) Level of PCNA at the mRNA and protein levels. Left
panel: mRNA level of PCNA from isolated mucosal scrapings of each group. Right panel: protein level of PCNA from
isolated IECs of each group. Representative immunoblots of isolated small-bowel IECs are given from each group. When
compared to that in the sham-treatment group, TPN administration significantly decreased the expression of jejunal PCNA
at the mRNA and protein levels, whereas GLM supplementation (75 mM) significantly prevented the down-regulation of
PCNA during TPN administration. Scale bars 	 50 m. Values are means  sd (error bars). ns, not significantly different.
*P  0.05.
Figure 3. TPN administration induces a signifi-
cant decrease in pAkt expressed by IECs, which is
reversed with GLM supplementation. Represen-
tative immunoblots of isolated small-bowel IECs
are given from each group. Compared with sham-
treatment, TPN administration significantly de-
creased expression of jejunal pAkt protein,
whereas GLM supplementation (75 mM) signifi-
cantly prevented the down-regulation of pAkt
during TPN administration. No difference in Akt
level was observed among the 3 groups. A mini-
mum of 3 experiments were used for each selec-
tion. Values are means  sd (error bars). ns, not
significantly different. *P  0.05.
2078 Vol. 28 May 2014 XIAO ET AL.The FASEB Journal  www.fasebj.org
tion had little to no adverse influence on the outcome
of the TPN mice.
IF staining with the tight junction (TJ) proteins occlu-
din and ZO-1 was then used to further address the
integrity of EBF in the TPN mice. Staining in the TPN
mice displayed a marked disconnection of the sharp,
mesh-like grid, as well as a loss of the colocalization of
ZO-1 and occludin that was seen in the sham mice (Fig.
4C). Administration of GLM (75 mM) to the TPN mice
actually augmented the loss of colocalization and led to a
greater reduction of occludin along the jejunal villi (Fig.
4C). Immunoblot analysis of the TJ proteins also demon-
strated a significant reduction of ZO-1 and occludin
protein expression in the TPN group, compared with that
in the sham mice. GLM supplementation led to an even
lower level of occludin protein expression but did not
affect ZO-1 protein expression, compared with that in the
nonsupplemented TPN group (Fig. 4D).
Loss of T1R3 signaling does not influence the
proproliferative effect of GLM, but promotes further
loss of EBF in TPN mice
As a common key component of the heterodimeric
umami TRs and sweet TRs, T1R3 plays a pivotal role in
intestinal luminal sensing (8). In light of the significant
alteration of T1R3 expression under TPN and GLM
treatments, T1R3KO mice were used to clarify the role
of T1R3 in the proproliferation and barrier-modulating
mechanism of GLM in the TPN mice. Although we
anticipated a blockade of GLM action in the T1R3KO
mice, no significant differences between them and the
wild-type (WT) mice were observed in the measure-
ment of jejunal villus length, crypt depth, and IEC
proliferation, when measured with PCNA or BrdU
staining in the TPN mice, with or without GLM treat-
ment. This finding was further confirmed with immu-
noblot analysis of PCNA protein (Fig. 5A–C). As well,
removal of T1R3 did not influence the up-regulation of
pAkt protein expression induced by GLM treatment in
the TPN mice. These results suggest that GLM-medi-
ated restoration of IEC proliferation and pAkt up-
regulation in TPN mice is independent of T1R3.
In contrast, the following results provide evidence of
a possible EBF-protective role for the T1R3 TR.
T1R3KO TPN mice showed significantly reduced TER
and increased FITC-dextran permeability compared
with WT TPN mice. Accordingly, the T1R3KO TPN
mice given GLM showed even further loss of TER and
Figure 4. GLM supplementation affects EBF in TPN mice. A, B) FITC-dextran permeability (A) and Ussing chamber results (B)
in each group. Note that TPN administration significantly induced an increase in FITC-dextran permeability and a decline in
TER of jejunal mucosa, compared to that in the sham-treatment group, whereas GLM supplementation at 75 mM intensified
the changes induced by TPN treatment. C) Representative images of IF staining for the TJ proteins occludin and ZO-1 in the
villus region, counterstained with DAPI. The abnormality of the TJ network, shown as a marked disconnection of the sharp,
mesh-like grid, was demonstrated in the jejunal villi from the TPNmice, compared to that in the sham-treatment group, whereas
GLM exposure at 75 mM intensified the abnormality. D) Protein expression of occludin and ZO-1 from isolated IECs in each
group. TPN administration significantly decreased the expression of both occludin and ZO-1 proteins, compared to that in the
sham-treatment group, whereas GLM supplementation (75 mM) caused a lower protein level of occludin but not of ZO-1 in the
TPN mice. Values are means  sd (error bars). ns, not significantly different. *P  0.05.
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Figure 5. T1R3KO promotes intestinal epithelial barrier dysfunction in TPN mice, but has no obvious influence on the
proproliferative effect of GLM in TPN mice. A–C) Jejunal villi and crypt measurements (A), PCNA- and BrdU-positive rate in
the intestinal mucosal crypt (B), and levels of PCNA and pAkt in each group (C), determined by immunoanalysis of isolated
small-bowel IECs. No significant difference was observed in these measurements between the T1R3KO and WT TPN mice, with
or without GLM supplementation. D, E) Ussing chamber (D) and FITC-dextran permeability (E) results of each group. T1R3KO
TPN mice showed significantly lower TER values (D) and higher FITC-dextran concentrations (E) than did the WT TPN mice,
with or without GLM supplementation. F) Protein expression of occludin and ZO-1 from isolated IECs in each group. G)
Representative images of IF staining for occludin and ZO-1 in the villus region, counterstained with DAPI. A significant decrease
in occludin protein expression was induced in T1R3KO TPNmice, as compared with that in WT TPNmice, with or without GLM
supplementation. Values are means  sd (error bars). ns, not significantly different. *P  0.05.
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an increase in permeability compared with that in the
WT mice (Fig. 5D, E), whereas no change in EBF was
detected in the chow-fed T1R3KO mice. Use of
T1R3KO mice also resulted in a significant down-
regulation of the occludin protein in TPN mice, with or
without GLM supplementation, compared with that in
WT TPN mice; however, there was no effect on ZO-1
expression (Fig. 5C). This finding was further con-
firmed with IF staining of TJ proteins (Fig. 5D), which
displayed an obviously weakened and interrupted oc-
cludin linear immunoreactivity along the villi. Taken
together, these data support the possibility that T1R3
serves an important role in maintaining homeostasis of
the EBF, potentially by maintaining an integrated TJ
configuration. It should be noted that the simple
removal of T1R3 is insufficient to alter EBF, as barrier
function was not affected in sham-treatment (enterally
fed) T1R3KO mice (data not shown).
mGluR5 antagonist MTEP has no obvious influence
on the proproliferative effect of GLM on TPN mice,
but significantly prevents EBF loss in TPN mice with
GLM supplementation
It has been shown that some mGluRs are involved in
the umami taste-sensing mechanism (27, 29). Of these
mGluRs in our PCR screening profile, mGluR5 was the
only one that displayed an obvious down-regulation in
the TPN group, which was reversed after GLM supple-
mentation. This finding suggests that mGluR5 is in-
volved in the regulatory mechanism of GLM’s action in
TPN mice. Most important, evidence is accumulating
that mGluR5 plays an important role in the modulation
of cell proliferation (30, 31). Hence, the classic
mGluR5 antagonist MTEP was used in the present study
to explore the role of mGluR5 in the GLM mechanism
in TPN mice. However, neither histologic analysis nor
proliferation assessment with PCNA or BrdU staining
demonstrated any influence of MTEP on the proprolif-
erative effect of GLM in the WT or T1R3KO TPN mice,
suggesting that the proliferation modulation of GLM is
independent of mGluR5 or T1R3, either alone or in
concert (Fig. 6A–C).
Given the influence of GLM on EBF in TPN mice,
assessment of EBF with MTEP treatment was performed
to determine whether mGluR5 is involved in this pro-
cess. TER and permeability results demonstrated that
MTEP treatment induced a 1.8-fold increase in TER
and a 2.9-fold decrease in FITC-dextran permeability in
TPN mice given GLM supplementation, compared with
those receiving saline treatment (Fig. 6D). This result
suggests that mGluR5 plays an important role in GLM-
mediated EBF dysfunction in TPN mice. This same
inhibition of EBF dysfunction by MTEP was also seen in
the T1R3KO TPN mice (Fig. 6D), further supporting
the importance of the mGluR5 pathway in the GLM-
mediated loss of EBF. Coincident with these physiolog-
ical changes was a significant (P0.05) preservation of
occludin protein levels in MTEP-treated TPN  GLM
mice (Fig. 6E). IF staining results showed that MTEP
treatment markedly attenuated the TJ abnormalities at
the jejunal villi in WT or T1R3KO TPN mice with GLM
supplementation (Fig. 6C), including prevention of the
loss of these junctional proteins along the interepithe-
lial space and of the internalization of occludin. It
should be noted that, as mentioned above, T1R3 re-
moval intensified barrier dysfunction in TPN  GLM
mice, whereas it appears that blocking mGluR5 activity
with MTEP neutralized the negative effect of T1R3KO
in GLM-treated TPN mice. This finding suggests a
differential action of GLM on different receptors,
where GLM appears to support EBF via T1R3 and to
degrade EBF via mGluR5.
GLM supplementation decreases plasma GLP-2 levels
of TPN mice via both T1R3 and mGluR5
Our previous work demonstrated that TPN results in a
significant loss of plasma GLP-2 and a down-regulation
of GLP-2 receptors (7). As some GLP-2 receptors are on
mucosal neuroendocrine cells, we next asked whether
GLM supplementation could stimulate luminal sensing
and drive an increase in GLP-2. The supplementation
of enterally fed (sham-treatment) mice with GLM led to
an unexpected dose-dependent decline in plasma
GLP-2 levels (Fig. 7A). GLM at the higher concentra-
tions (75 and 150 mM) resulted in a significant de-
crease in GLP-2, whereas 25 mM had no obvious effect
on plasma GLP-2 concentration in the sham-treatment
mice. Fig. 7B shows that TPN administration led to a
significant decline in GLP-2 levels, whereas GLM sup-
plementation at 75 mM further decreased the plasma
GLP-2 concentration to 
40% of that in the TPN
group. Most strikingly, blockade of T1R3 signaling and
mGluR5 both increased GLP-2 levels in the TPN 
GLM group in an additive fashion. This result suggests
a novel mechanism whereby the IEC proliferative effect
of GLM is negatively regulated by down-regulation of
the expression of GLP-2, potentially via enteroendo-
crine cells (T1R3 receptors) as well as other epithelial
cell populations (mGLuR5).
To better understand the mechanisms of these
changes, we looked at a time course of proglucagon
mRNA expression in the mucosa of the ileum and
colon, the 2 sites of proglucagon production, which is
post-translationally cleaved to GLP-2. Supplemental
Fig. S4 shows that proglucagon levels were similar to
those in enterally fed mice at 3 d of TPN, but signifi-
cantly declined by 1 wk. Interestingly, no differences in
proglucagon levels were seen between the TPN and
TPN  GLM groups, suggesting that a post-transcrip-
tional change is responsible for the decline in GLP-2
circulating levels. Alternatively, the differences may also
be due to changes in the degradation of GLP-2 by
endogenous peptidases.
DISCUSSION
In the present study, TPN administration led to significant
alterations in a series of luminal sensing-associated mole-
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cules, including T1Rs, GLMRs, and transporters in the
jejunal mucosa, whereas GLM supplementation at 75 mM
significantly influenced the alterations associated with
TPN. Notably, GLM supplementation in our TPN model
significantly prevented TPN-associated intestinal mucosal
atrophy via a stimulatory effect on IEC proliferation. GLM
administration at 75 mM also led to a partial loss of EBF
that was confined to our TPNmouse study group. Further
exploration of the mechanisms guiding this effect sug-
gests that two GPCRs, T1R3 andmGluR5, may be involved
in the mechanisms by which GLM modulates EBF,
whereby GLM stimulation of T1R3 appears to promote
Figure 6. mGluR5 antagonist MTEP significantly prevents intestinal epithelial barrier dysfunction, but has no obvious influence
on the proproliferative effect of GLM in TPN mice. A–C) Intestinal villi and crypt measurements (A), PCNA- and BrdU-positive
rate in the intestinal mucosal crypt (B), and levels of PCNA and pAkt (C). No significant differences in any of the measurements
were observed with MTEP exposure in the WT or T1R3KO TPN  GLM (75 mM) mice. D) Ussing chamber and FITC-dextran
permeability results. MTEP exposure significantly blocked the decline in TER and the increase in the FITC permeability rate
induced by TPN  GLM treatments (75 mM), when compared with saline treatment in WT or T1R3KO mice. E) Protein
expression of occludin and ZO-1 of isolated small-bowel IECs, determined by immunoanalysis. F) Representative images of IF
staining of the TJ proteins occludin and ZO-1 in the villus region, with DAPI counterstaining. MTEP exposure markedly
prevented the decline in occludin protein expression induced by TPN  GLM (75 mM) treatment when compared with saline
treatment in WT or T1R3KO mice. Values are means  sd (error bars). ns, not significantly different. *P  0.05.
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EBF, and GLM, acting on mGluR5, may have a negative
effect on barrier function. However, GLM stimulation of
these receptors failed to explain the positive effect on
epithelial proliferation in the TPN mice. Another finding
was that GLM supplementation further decreased plasma
GLP-2 levels in the TPNmice via both T1R3 and mGluR5
signaling, suggesting that the proproliferative effect of
GLM on the TPN mice is independent of GLP-2 release.
Collectively, these results demonstrated for the first time
that loss of gut luminal nutrient sensing contributes to
TPN-associated intestinal atrophy. Modulation of intesti-
nal luminal sensing pathways through GLM supplemen-
tation may not only drive IEC proliferation but also may
affect EBF of TPN mice. Clearly, further work is necessary
to understand what mechanisms drive this robust increase
in IEC proliferation and to determine the optimal dose of
GLM for preventing intestinal atrophy without promoting
epithelial barrier dysfunction during TPN administration.
Luminal nutrient sensing and TPN
Sensing of luminal contents is important in initiating
the appropriate response of digestion and absorption
of nutrients and can also neutralize and help remove
drugs, toxins, and microorganisms and play an impor-
tant role in host defense mechanisms (32–34). It has
been shown that the taste-sensing system plays a critical
role in luminal sensing in the GI tract, especially for
luminal nutrient signals (1, 5, 35, 36). The interaction
between luminal nutrients and TRs through G-coupled
proteins initiates various downstream pathways and
exerts different effects on the body that depend on the
combination of 3 T1Rs (4, 25, 35, 37–39).
TPN administration is associated with numerous
complications, ranging from an increase in infections
to a loss of immune reactivity, most likely owing to
mucosal atrophy (7). Although the underlying mecha-
nisms of TPN-associated complications are still not fully
established, it is clear that a major contributing factor is
enteral nutrient deprivation (28, 40). Indeed, the pres-
ent study supports our hypothesis that TPN administra-
tion leads to a significant alteration in mRNA expres-
sion of T1Rs, GLMRs, and transporters in the jejunal
mucosa, some of which were further confirmed with
immunoblot analysis. This result strongly suggests that
the loss of luminal nutrients during TPN administra-
tion widely affects nutrient taste sensing, nutrient trans-
port, and energy metabolism, but also could be a factor
in TPN-associated complications.
Of the T1Rs, T1R1 and T1R3 form a heterodimer
that responds to umami taste. These TRs were up-
regulated during TPN administration, whereas T1R2
moved in the opposite direction (reduction). As well,
the G-protein subunit G demonstrated a significant
down-regulation during TPN. Recent work has revealed
that intestinal T1Rs and other taste-signaling molecules
are under dynamic metabolic and luminal control for
feedback of GI function in response to luminal nutri-
ents (23). For example, intestinal T1R3 and G expres-
sion has been shown to be up-regulated in germ-free
mice, indicating that intestinal T1Rs may be adaptively
regulated by the absence of microbiota and driven by a
compensatory mechanism promoting the proximal in-
testine to detect and absorb more nutrients (26). Our
laboratory also confirmed the possible connection be-
tween the alteration of luminal microbiome and TPN-
associated intestinal atrophy (7). Thus, it is likely that
removal of food intake with TPN administration results
in reduced taste, which may trigger certain adaptive
machinery to modulate the level of T1Rs and G, in
order to detect the decreased nutrient signals. Interest-
ingly, a similar adaptive response of T1R2/T1R3 was
observed in reactive astrocytes under ischemia stimula-
tion, which is believed to maintain the glucose supply to
these stressed neurons (41).
GLM supplementation prevents the loss of
TPN-associated intestinal atrophy by promoting the
proliferation of IECs
GLM, as a nonessential amino acid, is well-known to be
responsible for umami taste (27). Akiba et al. (1, 9–11)
showed in an elegant study that luminal GLM perfusion
Figure 7. GLM supplementation decreased plasma GLP-2 levels
in TPN mice via both T1R3 and mGluR5. A) Supplementation
of enterally fed (sham-treatment) mice with GLM led to a
dose-dependent decline in plasma GLP-2 levels. GLM at the
higher concentration (75 and 150 mM) resulted in a significant
decrease in GLP-2, whereas 25 mM had no obvious effect on
plasma GLP-2 concentration in sham-treatment mice. B) TPN
administration led to a significant decline in GLP-2 levels, and
GLM supplementation at 75 mM further decreased plasma
GLP-2 concentrations in TPNmice. Block of T1R3 signaling and
mGluR5 both increased GLP-2 levels in the TPNGLM group
in an additive fashion. Values are means  sd (error bars). ns,
not significantly different. *P  0.05.
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activates duodenal mucosal defense mechanisms via
umami sensing. Therefore, one goal of the present
work was to investigate whether GLM supplementation
could similarly have benefit in preventing TPN-associ-
ated complications.
Indeed, in our study, GLM supplementation stimu-
lated the expression of most of the nutrient-sensing
molecules. Notably, the expression of all GPCRs, in-
cluding T1Rs and mGluRs, as well as the G protein G,
was up-regulated in the TPN mice after GLM treat-
ment, indicating that GLM could reactivate GPCR
signaling pathways that are negatively influenced by
TPN. In addition, GLM supplementation reversed the
decline in expression of SGLT-1, EAAT2, and EAAT3,
again suggesting that GLM can greatly improve the
transportation of luminal nutrients across the epithe-
lium that is inhibited by TPN (42).
Our previous work (43, 44) demonstrated that TPN
administration can induce intestinal mucosal atrophy,
which may be one of the fundamental events that
contribute to TPN-associated clinical complications. In
the present study, we showed that GLM supplementa-
tion could significantly prevent intestinal mucosal atro-
phy in the TPN mice via promotion of IEC prolifera-
tion. In accordance, GLM has been shown to be
involved in the mucosal healing process and may well
mediate this action by IECs that use GLM as an energy
source for cell proliferation, as suggested in previous
studies (45, 46). Thus, GLM supplementation in the
TPN model may provide an important energy source
that drives this proliferation (47).
pAkt is an important molecule that plays a central
role in regulating IEC proliferation (48). Our previous
work also showed that TPN leads to decreased pAkt,
which contributes to intestinal atrophy, whereas pAkt
activation leads to a significant prevention of mucosal
atrophy (19). In the present work, GLM led to a
significant increase in pAkt expression, which was oth-
erwise down-regulated in the TPN group. This result
suggests that pAkt signaling plays an important role in
the GLM proproliferation mechanism (19). In addi-
tion, it is possible that GLM via conversion into glu-
tamine exerts protective effects on IECs, which itself
has been shown to have strong benefits in maintaining
IEC proliferation (49, 50).
Of note, because the nutrient was delivered orally
in the present study, we cannot rule out the possibil-
ity that GLM’s effects derive from sense of taste via
activation of umami receptors in the tongue, which
can also indirectly regulate multiple intestinal phys-
iological functions via the gut–brain axis (51).
Therefore, in subsequent experiments, luminal GLM
perfusion by gavaging may be a better way to observe
the direct effect of GLM on the intestinal mucosa.
GLM supplementation affects EBF in TPN mice
A loss of EBF during TPN administration is also be-
lieved to contribute to the increased rate of systemic
infections and septicemia (28). Surprisingly, it appears
that GLM supplementation at 75 mM affected EBF in
the TPN mice, as manifested by increased permeability
and even worse disarrangement and down-regulation
of the occludin protein. It should be noted that no
obvious change in EBF was observed in lower doses of
GLM (25 mM) in the TPN mice as well at 75 mM of
GLM in the chow-fed mice, suggesting that the influ-
ence of GLM on EBF in TPN mice is highly dose
dependent, as reported in other works (12, 52).
To date, the exact role of GLM in modulating EBF
has yet to be defined by the limited available data. For
example, Vermeulen et al. (53) showed that exposure
to GLM significantly reduces the phorbol-12,13-dibu-
tyrate-induced hyperpermeability of IECs. As well,
blocking the conversion from glutamine to GLM has
been shown to inhibit the barrier-protective effect of
glutamine (49, 53). A recent study may help us to
illustrate the influence of GLM on EBF of the TPN
mice. Znalesniak et al. (54) demonstrated that IEC
restitution induced by epidermal growth factor leads to
a significant down-regulation of the cell-cell contact-
associated genes, including TJ-associated proteins,
which is thought to severely affect EBF. Thus, it is likely
that the rapid proliferation and migration of IECs
along the crypt–villus axis in the GLM-treated TPN
group led to this loss of barrier function. More investi-
gation is needed to further determine the dose–effect
relationship of GLM in both in vitro and in vivo tests, to
clarify the exact role of GLM in EBF, and to precisely
determine the optimal dose of GLM in preventing
TPN-associated intestinal atrophy and avoid negative
effects on the EBF.
Possible role of T1R3 and mGluR5 in GLM’s effects
on IEC proliferation and EBF
As the common component of the T1R1/T1R3 and
T1R2/T1R3 heterodimers, T1R3 is generally thought
to play a pivotal role in the luminal sensing machinery
(8). Loss of T1R3 (via transgenic KOs) led to total loss
of preference for both umami stimuli and artificial
sweeteners and had only minimal response to sugars
(55). Quite unexpectedly, the use of T1R3KO mice
failed to influence the effect of GLM on IEC prolifer-
ation, but promoted a further weakening of EBF in the
TPN mice, with or without GLM supplementation.
Thus, the effect of GLM on IEC proliferation in the
TPN mice appears not to be T1R3 dependant. It is
possible that other mechanisms drive this proliferative
action. Emerging evidence suggests that besides T1R3,
there are other receptors responsible for the umami
taste. Yasumatsu et al. (27) recently reported that
multiple receptors and transduction pathways, as well
as multiple types of GLM-sensitive gustatory nerve
fibers, are involved in umami taste sensing. Moreover,
T1R3KO in different models caused only a partial
reduction in the capability of detecting and discrimi-
nating MSG and sucrose (56). Notably, in our study, the
loss of T1R3 exacerbated EBF in TPN mice, suggesting
that T1R3 is involved in maintaining EBF. The signifi-
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cant up-regulation of T1R3 in TPN or TPN  GLM
mice may represent a dynamic protective role of T1R3
in maintaining barrier integrity against external stimu-
lus. In addition, no obvious change in EBF was ob-
served in T1R3KO normal or sham mice, indicating
that T1R3 may not be a pivotal factor in EBF regulation.
mGluR5 is another type of GPCR, belonging to the
group I metabotropic GLM receptors (57). Evidence is
accumulating that mGluR5 plays an important role in
the modulation of cell proliferation (30, 31, 58). How-
ever, it appears that mGluR5 is not involved in the
mechanism by which GLM increases IEC proliferation
in TPN mice. Furthermore, MTEP failed to block the
proproliferative effect of GLM in T1R3KO TPN mice,
suggesting that the proliferative action of GLM is
independent of mGluR5 or T1R3, either alone or in
concert. Interestingly, mGluR5 is involved in the effect
of GLM on EBF in TPNmice, as the mGluR5 antagonist
MTEP significantly alleviated the reduced EBF of TPN
mice with GLM supplementation. It appears that T1R3
and mGluR5 have distinct functions in EBF regulation:
stimulation of T1R3 may promote barrier function,
whereas mGluR5 may participate in GLM-induced EBF
dysfunction in TPN mice (summarized in Fig. 8).
GLP-2 is not involved in the proproliferative effect of
GLM on TPN mice
GLP-2 is a nutrient-dependent, proglucagon-derived,
intestinotrophic hormone that has been shown to
support intestinal epithelial growth during TPN admin-
istration or in patients with short bowel syndrome (59,
60). A recent report showed that GLM increases GLP-2
release from the GI tract, which is well recognized to
stimulate IEC proliferation (61). Accordingly, we hy-
pothesized that the increase in GLP-2 release is part of
the mechanism that accounts for GLM’s profound
action in driving IEC proliferation. Surprisingly, sup-
plementation with GLM led to a dose-dependent de-
cline in plasma GLP-2 levels in either enterally fed or
TPN mice, whereas blockade of T1R3 signaling and
mGluR5 both increased GLP-2 levels in an additive
fashion, suggesting that both receptors sense intralumi-
nal GLM, leading to a decline in GLP-2 in a negative-
Figure 8. Schematic view of the possible mechanisms by which GLM modulates intestinal epithelial proliferation and alters EBF
in mice receiving TPN. TPN administration leads to significant alterations in a series of luminal sensing–associated molecules,
including T1Rs, mGluRs, G, and transporters in the intestinal mucosa. This disturbance of luminal sensing machinery may
contribute to the development of mucosal atrophy and loss of intestinal EBF during TPN treatment. Luminal GLM
supplementation stimulates the expression of GPCRs, such as T1R3, mGluR5, and the G-protein subunit G, thereby
reactivating the luminal sensing signaling pathways that are down-regulated by TPN. Subsequently, GLM promotes IEC
proliferation in TPN mice through activating the pAkt/mTOR signaling pathway, which may be initiated via some presently
poorly characterized TRs localized on small-bowel enteroendocrine cells (19, 62). In addition, GLM supplementation leads to
a decline in circulating plasma GLP-2 levels in TPN mice, suggesting that the proproliferative effect of GLM on TPN mice is
independent of GLP-2 release. As well, by inhibiting the expression of the TJ protein occludin in IECs, GLMmay lead to a partial
loss of EBF in TPN mice. Of note, T1R3 and mGluR5 appear to have distinct functions in EBF regulation by GLM, whereby
stimulation of T1R3 by GLM promotes barrier function, whereas mGluR5 may participate in GLM-induced epithelial barrier
dysfunction in TPN mice. In addition, GLM could improve the transportation of luminal nutrients across the epithelium, which
is normally down-regulated with TPN, by stimulating the expression of multiple transporters such as EAAT2, EAAT3, and
SGLT-1.
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regulatory fashion. It is possible that this is a counter-
regulatory control mechanism that prevents an
otherwise excessive increase in IEC proliferation in-
duced by GLM. As noted in the Results section, TPN
administration over 3 d to 1 wk led to a significant
decline in proglucagon expression in the ileum and
colon, the two sources of proglucagon, the peptide
from which GLP-2 is derived. This decline occurred in
the TPN and TPNGLM groups. We were surprised
that the mRNA levels did not correlate at 1 wk with the
decline in blood levels of GLP-2. A variety of mecha-
nisms may contribute to such differences, including
changes in the post-transcriptional expression of GLP-2
or changes in the degradation of GLP-2 by endogenous
peptidases. Further work is needed to improve our
understanding of these unique findings.
There are some shortcomings to the study, in that
the complete control of electrolyte delivery in the GLM
group may not have been perfectly matched to that in
the TPN group without GLM, but the disparity was
thought to be slight and did not account for the
substantial changes detected in this study. Taken to-
gether, evidence from the present study shows for the
first time the relationship between intestinal luminal
nutrient-sensing mechanisms and TPN-associated com-
plications. GLM supplementation at 75 mM signifi-
cantly prevents TPN-associated intestinal atrophy. Two
GPCRs, T1R3 and mGluR5, were not involved in the
proproliferation mechanism of GLM in IECs, but
played distinct and divergent roles in modulating the
EBF of TPN mice. GLM supplementation further de-
creased plasma GLP-2 levels in TPNmice via both T1R3
and mGluR5, suggesting that the proproliferative effect
of GLM on the TPN mice may be independent of
GLP-2 release. More research is needed to understand
the important role of luminal sensing in IEC prolifer-
ation and EBF modulation, as well as to determine the
optimal dose of GLM to prevent intestinal atrophy
without promoting epithelial barrier dysfunction under
TPN administration. The use of GLM may be beneficial
in preventing the development of clinical TPN-associ-
ated atrophy.
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